Viking Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated May 26, 2016, details the results of the 2016 Annual Meeting of Stockholders held on that date. The filing covers the election of directors and the ratification of the independent registered public accounting firm.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
As of the record date (April 4, 2016), 9,683,741 shares of common stock were issued and outstanding. Stockholders approved two proposals:
- Proposal 1: Election of Class I Director
- Matthew W. Foehr was elected to serve until the 2019 Annual Meeting.
- Votes For: 5,666,744
- Votes Withheld: 9,338
- Broker Non-Votes: 939,090
- Proposal 2: Ratification of Independent Auditor
- Marcum LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2016.
- Votes For: 6,580,666
- Votes Against: 27,394
- Abstentions: 7,112
- Broker Non-Votes: 0
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. Detailed descriptions of the proposals were referenced as being contained in the definitive proxy statement filed on April 12, 2016.
Investor Verification Checklist
- Verify the term length and qualifications of the newly elected director, Matthew W. Foehr.
- Confirm the engagement terms and fees for Marcum LLP as the independent auditor for fiscal year 2016.
- Review the definitive proxy statement filed on April 12, 2016, for detailed background on the proposals.
- Note the significant number of broker non-votes (939,090) on the director election, which may indicate shares held in street name where brokers lacked discretionary voting power.